Experts Video Reports: Genitourinary Cancers track

Reporting from ASCO 2022 Annual Meeting in Chicago, Ian Davis comments on Prostate Cancer latest data in the metastatic setting.

Reporting from the ASCO Genitourinary Symposium 2022, Fred Saad provides an overview of practice changing studies with combination therapy in advanced prostate cancer. He features the improved rPFS demonstrated in PROpel and MAGNITUDE with a combination of PARPi with abiraterone or AAP in patients with mCRPC. He also discusses reduction in the risk of death by adding darolutamide to ADT + docetaxel in patients with mHSPC and other endpoints fovouring the triplet therapy.

Reporting from the ASCO Genitourinary Symposium 2022, Petros Grivas comments on data from studies that support further evaluation in urothelial cancer, in particular sacituzumab govitecan + pembrolizumab in the metastatic setting for platinum-refractory disease, nivolumab + trastuzumab deruxtecan in patients with HER2-expressing tumour, and single agent enfortumab vedotin in the neoadjuvant setting before radical cystectomy in patients who are cisplatin-ineligible.

Reporting from the ESMO Congress 2021, Richard Cathomas gives an overview of important study results covering metastatic prostate cancer. He begins by covering the informative findings from the ARCHES study testing enzalutamide plus ADT in hormone-sensitive prostate cancer. Then he comments on results from the castration resistant setting in the COSMIC-021 trial testing a combination of atezolizumab + cabozantinib, and finally, discusses results from the SAKK 08/16 study about darolutamide maintenance therapy.

Reporting from 2021 ASCO Annual Meeting, Primo "Lucky" Lara reports on positive results from the VISION study testing the addition of lutetium 177 to standard of care in metastatic castration-resistant prostate cancer, and discusses the challenges of implementing nuclear medicine therapy in the clinic.
He also comments on metastatic castration-sensitive prostate cancer results from the PEACE-1 study with a 2x2 factorial design of abiraterone plus prednisone and/or local radiotherapy, and results from the SWOG S1216 study comparing ADT plus TAK-700 vs ADT plus bicalutamide.

Reporting from the 2021 Genitourinary Cancers Symposium, Matthew Galsky features practice changing results from Urothelial Carcinoma studies testing adjuvant nivolumab after radical surgery in muscle-invasive disease with high risk for relapse, and evaluating enfortumab vedotin vs standard chemotherapy in patients with previously treated advanced disease.

Reporting from the 2021 Genitourinary Cancers Symposium, Karen Knudsen comments on results from CRPC studies looking at molecular determinants associated with long term response to apalutamide in the SPARTAN study, and the final results from the ACIS study testing the addition of apalutamide to abiraterone and prednisone in metastatic disease.
She also gives an overview of the final results from the TITAN study testing apalutamide in metastatic castration-sensitive setting receiving ADT.

Reporting from the ESMO Virtual Congress 2020, Maria De Santis comments on promising therapeutic options and practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).
She emphasises the importance of testing CRPC patients for genomic alterations (BRCA1, BRCA2 or ATM) as soon as the cancer metastasises, to identify those who could benefit from targeted treatment options.

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Powles comments on practice changing results in the management of urothelial cancer and new biomarker data for improved patients selection.

Reporting from ESMO 2019 Congress, Johann de Bono comments on practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).

He features the results from the CARD study on best sequence treatment and from the PROfound trial with olaparib in patients whose tumours have homologous recombination repair gene alterations. He explains the need for molecular profiling of advanced prostate cancer which may have a major impact on prostate cancer management in the future.

E. Efstathiou reports on study results presented on prostate cancer at ASCO 2019. She explains the benefits of adding hormonal agents early in the disease spectrum, and discusses the prospect of combinatorial strategies based on biomarkers selection.

Reporting from AACR 2019 in Atlanta, F-C. Bidard comments on clinical utility of CTCs and ctDNA as biomarkers based on the results from two studies in breast and prostate cancer.

Reporting from ASCO GU, Silke Gillessen (Manchester) comments on the results from major studies on Prostate Cancer that were presented during this meeting:

• Abstract 140 ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer; K. Fizazi
• Abstract 687: Phase 3 study of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: The ARCHES trial; A.J. Armstrong

Reporting from ASCO GU, Bradley McGregor comments on Renal cell carcinoma studies results: JAVELIN, KEYNOTE-426, CheckMate 214, KEYNOTE-427 and a phase II study of atezolizumab and bevacizumab